THIS IS BIG potential news for the CRC, Lung and Pancreatic cancer worlds. Just announced: the initiation of a KRAS-mutant directed personalized cellular therapy Phase 1 clinical trial for SOME segments of the KRAS-mutant CRC, Lung and pancreatic cancer patient populations - it will depend on the exact mutation and your HLA type. They have not announced the exact mutations or required HLA types yet - but will soon. I will post as soon as available.
The "drugs" will be living immune cells.
It is essentially an effort to commercialize in a more logistically efficient way the NIH TIL trial but limited to only certain slices of patients with certain KRAS-mutations and HLA-types
Expect a lot more info to be coming out soon. From a technology point of view, this is BIG. I'll be writing a science blog about it soon.
I'll announce (and explain) more details as they come out - this is just an exciting teaser press release, but they say trial will start in 2016.http://www.businesswire.com/news/home/2 ... 006760/en/
Welcome to the future!
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/2016 Colondar 2.0 ModelDK37 Science Posts List